Navigator Identification of Breast Biopsy Results: A Time Analysis of Biopsy Results and Variance in Turnaround TimeDressman, Laurie A.Journal of Oncology Navigation & Survivorship
turnaround time forfasttreatment decisions.5‡ for >92% of patientseven before the Guardant Access Program kicks in.§ Biomarker Panel Guardant360 isguideline-completeacross all advanced solid tumors.2,6-9,‖ Covered guideline-recommended biomarkers for common cancer types: ...
Faster turnaround time from sample to results Help capture more of the heterogeneity of the tumor May lead to improvements in standard of care in the future We now know that cancer is a molecular disease. To better advance cance...
Time to Results Turnaround analysis revealed that the median time from pathologic diagnosis to receipt of the tissue report on the last biomarker was 21.5 days (range = 7–45 days), whereas the median time from blood draw to receiving cell-free DNA findings was 10 days (range ...
turnaround time, thereby reducing the treatment lag time. Cancer patients in hospitals undergo routine monitoring for analysis of resistance to treatment. Chemotherapy has long been a successful and dependable cancer treatment. Chemotherapy may be used to treat cancer or to improve quality of life by...
Interactive ToolsSponsored Biomarker ConsortiumSubscribe Choose Specialty Biosimilars Brain Cancer Breast CancerBreast Cancer CAR T-cell Therapy COVID-19 Disparities in Cancer Care Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer ...
The language around the role of LBx in the NCCN guidelines for NSCLC and breast cancer were also updated, supporting “complementary testing [tissue and LBx] to reduce turnaround time and increase yield of targetable alteration detection” in NSCLC, and considering reflexing to the other [tissue...
U.S. Biopsy Devices Market size reached USD 934.3 Million in 2023 to reach USD 1,244.9 Million by 2032 at a CAGR of 3.14% during 2024-2032.
Liquid biopsy-based biomarkers have garnered special interest in the field of precision oncology as they possess several advantages over tissue-based biomarkers including their minimally-invasive nature, rapid turnaround collection time, convenience and feasibility to obtain several samples from patients acr...
Liquid biopsy-based biomarkers have garnered special interest in the field of precision oncology as they possess several advantages over tissue-based biomarkers including their minimally-invasive nature, rapid turnaround collection time, convenience and feasibility to obtain several samples from patients acr...